user

Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice

被引：30
|
作者：
Lees, CJ
Apostolopoulos, V
Acres, B
Ramshaw, I
Ramsay, A
Ong, CS
McKenzie, IFC
机构：
[1] Austin Res Inst, Melbourne, Vic 3084, Australia
[2] Victoria Univ Technol, Ctr Bioproc & Food Technol, Werribee, Vic 3030, Australia
[3] Transgene SA, Dept Immunobiol, F-67082 Strasbourg, France
[4] Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol, Canberra, ACT 2601, Australia
来源：
VACCINE | 2000年 / 19卷 / 2-3期
关键词：
cytokines; transgenic; MUC1;
D O I：
10.1016/S0264-410X(00)00065-7
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic;mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：158 / 162
页数：5
相关论文
共 50 条
  • [1] Tumour immunotherapy against MUC1 expressing tumours using mannan MUC1
    Apostolopoulos, V
    Pietersz, GA
    Acres, B
    Osinski, C
    Thynne, G
    Xing, PX
    Karanikas, V
    Vaughan, HA
    Hwang, L
    Popovski, V
    Lees, C
    Ong, CS
    McKenzie, IFC
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 315 - 320
  • [2] MUC1 immunotherapy
    Beatson, Richard E.
    Taylor-Papadimitriou, Joyce
    Burchell, Joy M.
    IMMUNOTHERAPY, 2010, 2 (03) : 305 - 327
  • [3] T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice
    Dongshu Chen
    Shigeo Koido
    Yongqing Li
    Sandra Gendler
    Jianlin Gong
    Breast Cancer Research and Treatment, 2000, 60 : 107 - 115
  • [4] T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice
    Chen, DS
    Koido, S
    Li, YQ
    Gendler, S
    Gong, JL
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 60 (02) : 107 - 115
  • [5] MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines
    Acres, B
    Apostolopoulos, V
    Balloul, JM
    Wreschner, D
    Xing, PX
    Ali-Hadji, D
    Bizouarne, N
    Kieny, MP
    McKenzie, IFC
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) : 588 - 594
  • [6] MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines
    Bruce Acres
    Vasso Apostolopoulos
    Jean-Marc Balloul
    Danny Wreschner
    Pei-Xiang Xing
    Dahlila Ali-Hadji
    Nadine Bizouarne
    Marie Paule Kieny
    Ian F.C. McKenzie
    Cancer Immunology, Immunotherapy, 2000, 48 : 588 - 594
  • [7] Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases
    Shi, Frank F.
    Gunn, George R.
    Snyder, Linda A.
    Goletz, Theresa J.
    VACCINE, 2007, 25 (17) : 3338 - 3346
  • [8] Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
    Rowse, GJ
    Tempero, RM
    VanLith, ML
    Hollingsworth, MA
    Gendler, SJ
    CANCER RESEARCH, 1998, 58 (02) : 315 - 321
  • [9] Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
    Tempero, RM
    Morikane, K
    Vanlith, ML
    Gendler, SJ
    Hollingsworth, MA
    FASEB JOURNAL, 1998, 12 (05): : A891 - A891
  • [10] Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice
    Stergiou, Natascha
    Glaffig, Markus
    Jonuleit, Helmut
    Schmitt, Edgar
    Kunz, Horst
    CHEMMEDCHEM, 2017, 12 (17) : 1424 - 1428
12345